Drugs / Shengxuening Tablets
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05784870 | Feb 2023 → Dec 2024 | aregenerative anemia | Zhongnan Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shengxuening Tablets | “Shengxuening Tablets are derived from silkworm excrement.” NCT05784870 ↗ |
| Known as | Shengxuening Tablet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05784870 ↗ |
| Action | Activate | “These results indicated that Shengxuening Tablets promoted the recovery of hematopoietic function in myelosuppressive models by increasing the secretion of hematopoietic...” NCT05784870 ↗ |
| Route | Oral | “Oral treatment with Shengxuening Tablets 1 week before chemotherapy” NCT05784870 ↗ |
| Target | JAK2 | “These results indicated that Shengxuening Tablets promoted the recovery of hematopoietic function in myelosuppressive models by increasing the secretion of hematopoietic...” NCT05784870 ↗ |
| Target | STAT3 | “These results indicated that Shengxuening Tablets promoted the recovery of hematopoietic function in myelosuppressive models by increasing the secretion of hematopoietic...” NCT05784870 ↗ |